Skip to main content
Erschienen in: European Journal of Clinical Microbiology & Infectious Diseases 9/2010

01.09.2010 | Brief Report

Activity of doripenem against extended-spectrum β-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa isolates

verfasst von: C. Betriu, M. Gómez, F. López-Fabal, E. Culebras, I. Rodríguez-Avial, J. J. Picazo

Erschienen in: European Journal of Clinical Microbiology & Infectious Diseases | Ausgabe 9/2010

Einloggen, um Zugang zu erhalten

Abstract

The in vitro activity of doripenem was evaluated against a recent collection of extended-spectrum β-lactamase (ESBL)-producing Enterobacteriaceae and Pseudomonas aeruginosa isolates (201 ESBL-producing Enterobacteriaceae [153 Escherichia coli and 48 Klebsiella pneumoniae] and 201 P. aeruginosa). Comparator agents included amikacin, tobramycin, ciprofloxacin, cefepime, cefotaxime, ceftazidime piperacillin-tazobactam, imipenem, and meropenem. Both doripenem and meropenem inhibited 100% of the ESBL-producing Enterobacteriaceae at ≤0.5 µg/mL. For these isolates, the MIC90 of doripenem (0.12 µg/mL) was 4-fold lower than that of imipenem (0.5 µg/mL). Against P. aeruginosa, the MIC90 of doripenem and meropenem was 2 µg/mL, 4-fold lower than that of imipenem (8 µg/mL). At an MIC of ≤2 µg/mL, doripenem, meropenem, and imipenem inhibited 90.5%, 89.6%, and 82.1% of P. aeruginosa isolates, respectively. Doripenem maintained activity against imipenem-nonsusceptible isolates of P. aeruginosa; at an MIC of ≤4 µg/mL, it inhibited 15 of the 25 isolates with MICs for imipenem of >4 µg/mL. Doripenem is active against ESBL-producing Enterobacteriaceae and P. aeruginosa isolates. Its activity is similar to that of meropenem and slightly better than that of imipenem. The results of this study suggest that doripenem could be an alternative therapeutic agent for infections caused by these organisms.
Literatur
1.
Zurück zum Zitat Pitout JD, Nordmann P, Laupland KB, Poirel L (2005) Emergence of Enterobacteriaceae producing extended-spectrum beta-lactamases (ESBLs) in the community. J Antimicrob Chemother 56:52–59CrossRefPubMed Pitout JD, Nordmann P, Laupland KB, Poirel L (2005) Emergence of Enterobacteriaceae producing extended-spectrum beta-lactamases (ESBLs) in the community. J Antimicrob Chemother 56:52–59CrossRefPubMed
2.
Zurück zum Zitat Livermore DM (2002) Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare? Clin Infect Dis 34:634–640CrossRefPubMed Livermore DM (2002) Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare? Clin Infect Dis 34:634–640CrossRefPubMed
3.
Zurück zum Zitat Quinn JP (1998) Clinical problems posed by multiresistant nonfermenting gram-negative pathogens. Clin Infect Dis 27(Suppl 1):S117–S124CrossRefPubMed Quinn JP (1998) Clinical problems posed by multiresistant nonfermenting gram-negative pathogens. Clin Infect Dis 27(Suppl 1):S117–S124CrossRefPubMed
4.
Zurück zum Zitat Castanheira M, Jones RN, Livermore DM (2009) Antimicrobial activities of doripenem and other carbapenems against Pseudomonas aeruginosa, other nonfermentative bacilli, and Aeromonas spp. Diagn Microbiol Infect Dis 63:426–433CrossRefPubMed Castanheira M, Jones RN, Livermore DM (2009) Antimicrobial activities of doripenem and other carbapenems against Pseudomonas aeruginosa, other nonfermentative bacilli, and Aeromonas spp. Diagn Microbiol Infect Dis 63:426–433CrossRefPubMed
5.
Zurück zum Zitat Ge Y, Wikler MA, Sahm DF, Blosser-Middleton RS, Karlowsky JA (2004) In vitro antimicrobial activity of doripenem, a new carbapenem. Antimicrob Agents Chemother 48:1384–1496CrossRefPubMed Ge Y, Wikler MA, Sahm DF, Blosser-Middleton RS, Karlowsky JA (2004) In vitro antimicrobial activity of doripenem, a new carbapenem. Antimicrob Agents Chemother 48:1384–1496CrossRefPubMed
6.
Zurück zum Zitat Mendes RE, Rhomberg PR, Bell JM, Turnidge JD, Sader HS (2009) Doripenem activity tested against a global collection of Enterobacteriaceae, including isolates resistant to other extended-spectrum agents. Diagn Microbiol Infect Dis 63:415–425CrossRefPubMed Mendes RE, Rhomberg PR, Bell JM, Turnidge JD, Sader HS (2009) Doripenem activity tested against a global collection of Enterobacteriaceae, including isolates resistant to other extended-spectrum agents. Diagn Microbiol Infect Dis 63:415–425CrossRefPubMed
7.
Zurück zum Zitat Pillar CM, Torres MK, Brown NP, Shah D, Sahm DF (2008) In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States. Antimicrob Agents Chemother 52:4388–4399CrossRefPubMed Pillar CM, Torres MK, Brown NP, Shah D, Sahm DF (2008) In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States. Antimicrob Agents Chemother 52:4388–4399CrossRefPubMed
8.
Zurück zum Zitat Wexler HM, Engel AE, Glass D, Li C (2005) In vitro activities of doripenem and comparator agents against 364 anaerobic clinical isolates. Antimicrob Agents Chemother 49:4413–4417CrossRefPubMed Wexler HM, Engel AE, Glass D, Li C (2005) In vitro activities of doripenem and comparator agents against 364 anaerobic clinical isolates. Antimicrob Agents Chemother 49:4413–4417CrossRefPubMed
9.
Zurück zum Zitat Clinical and Laboratory Standards Institute (CLSI) (2009) Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard, 8th edition. M7-A8, vol. 29, no. 2. CLSI, Wayne, PA Clinical and Laboratory Standards Institute (CLSI) (2009) Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard, 8th edition. M7-A8, vol. 29, no. 2. CLSI, Wayne, PA
10.
Zurück zum Zitat Clinical and Laboratory Standards Institute (CLSI) (2009) Performance standards for antimicrobial susceptibility testing. 19th informational supplement. M100-S19, vol. 29, no. 3. CLSI, Wayne, PA Clinical and Laboratory Standards Institute (CLSI) (2009) Performance standards for antimicrobial susceptibility testing. 19th informational supplement. M100-S19, vol. 29, no. 3. CLSI, Wayne, PA
13.
Zurück zum Zitat Horiuchi M, Kimura M, Tokumura M, Hasebe N, Arai T, Abe K (2006) Absence of convulsive liability of doripenem, a new carbapenem antibiotic, in comparison with beta-lactam antibiotics. Toxicology 222:114–124CrossRefPubMed Horiuchi M, Kimura M, Tokumura M, Hasebe N, Arai T, Abe K (2006) Absence of convulsive liability of doripenem, a new carbapenem antibiotic, in comparison with beta-lactam antibiotics. Toxicology 222:114–124CrossRefPubMed
14.
Zurück zum Zitat Lucasti C, Jasovich A, Umeh O, Jiang J, Kaniga K, Friedland I (2008) Efficacy and tolerability of IV doripenem versus meropenem in adults with complicated intra-abdominal infection: a phase III, prospective, multicenter, randomized, double-blind, noninferiority study. Clin Ther 30:868–883CrossRefPubMed Lucasti C, Jasovich A, Umeh O, Jiang J, Kaniga K, Friedland I (2008) Efficacy and tolerability of IV doripenem versus meropenem in adults with complicated intra-abdominal infection: a phase III, prospective, multicenter, randomized, double-blind, noninferiority study. Clin Ther 30:868–883CrossRefPubMed
15.
Zurück zum Zitat Mushtaq S, Ge Y, Livermore DM (2004) Doripenem versus Pseudomonas aeruginosa in vitro: activity against characterized isolates, mutants, and transconjugants and resistance selection potential. Antimicrob Agents Chemother 48:3086–3092CrossRefPubMed Mushtaq S, Ge Y, Livermore DM (2004) Doripenem versus Pseudomonas aeruginosa in vitro: activity against characterized isolates, mutants, and transconjugants and resistance selection potential. Antimicrob Agents Chemother 48:3086–3092CrossRefPubMed
16.
Zurück zum Zitat Sakyo S, Tomita H, Tanimoto K, Fujimoto S, Ike Y (2006) Potency of carbapenems for the prevention of carbapenem-resistant mutants of Pseudomonas aeruginosa: the high potency of a new carbapenem doripenem. J Antibiot (Tokyo) 59:220–228 Sakyo S, Tomita H, Tanimoto K, Fujimoto S, Ike Y (2006) Potency of carbapenems for the prevention of carbapenem-resistant mutants of Pseudomonas aeruginosa: the high potency of a new carbapenem doripenem. J Antibiot (Tokyo) 59:220–228
17.
Zurück zum Zitat Fujimura T, Anan N, Sugimori G, Watanabe T, Jinushi Y, Yoshida I, Yamano Y (2009) Susceptibility of Pseudomonas aeruginosa clinical isolates in Japan to doripenem and other antipseudomonal agents. Int J Antimicrob Agents 34:523–528CrossRefPubMed Fujimura T, Anan N, Sugimori G, Watanabe T, Jinushi Y, Yoshida I, Yamano Y (2009) Susceptibility of Pseudomonas aeruginosa clinical isolates in Japan to doripenem and other antipseudomonal agents. Int J Antimicrob Agents 34:523–528CrossRefPubMed
Metadaten
Titel
Activity of doripenem against extended-spectrum β-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa isolates
verfasst von
C. Betriu
M. Gómez
F. López-Fabal
E. Culebras
I. Rodríguez-Avial
J. J. Picazo
Publikationsdatum
01.09.2010
Verlag
Springer-Verlag
Erschienen in
European Journal of Clinical Microbiology & Infectious Diseases / Ausgabe 9/2010
Print ISSN: 0934-9723
Elektronische ISSN: 1435-4373
DOI
https://doi.org/10.1007/s10096-010-0974-3

Weitere Artikel der Ausgabe 9/2010

European Journal of Clinical Microbiology & Infectious Diseases 9/2010 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.